{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T23:16:07Z","timestamp":1788131767899,"version":"build-2803163510"},"reference-count":72,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Individuals experiencing subjective cognitive decline (SCD) are at an increased risk of developing mild cognitive impairment and dementia. Early identification of SCD and neurodegenerative diseases using biomarkers may help clinical decision-making and improve prognosis. However, few cross-sectional and longitudinal studies have explored plasma biomarkers in individuals with SCD using immunomagnetic reduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To identify plasma biomarkers for SCD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Fifty-two participants [38 with SCD, 14 healthy controls (HCs)] underwent baseline assessments, including measurements of plasma A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      , A\u03b2\n                      <jats:sub>40<\/jats:sub>\n                      , t-tau, p-tau, and \u03b1-synuclein using immunomagnetic reduction (IMR) assays, cognitive tests and the Mini-Mental State Examination (MMSE). Following initial cross-sectional analysis, 39 individuals (29 with SCD, 10 HCs) entered a longitudinal phase for reassessment of these biomarkers and the MMSE. Biomarker outcomes across different individual categories were primarily assessed using the area under the receiver operating characteristic (ROC) curve. The SCD subgroup with an MMSE decline over one point was compared to those without such a decline.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Higher baseline plasma A\u03b2\n                      <jats:sub>1-42<\/jats:sub>\n                      levels significantly discriminated participants with SCD from HCs, with an acceptable area under the ROC curve (AUC) of 67.5% [95% confidence interval (CI), 52.7\u201380.0%]. However, follow-up and changes in MMSE and IMR data did not significantly differ between the SCD and HC groups (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;gt;\u20090.05). Furthermore, lower baseline plasma A\u03b2\n                      <jats:sub>1-42<\/jats:sub>\n                      levels were able to discriminate SCD subgroups with and without cognitive decline with a satisfied performance (AUC, 75.0%; 95% CI, 55.6\u201389.1%). At last, the changes in t-tau and A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      \u00d7\u2009t-tau could differentiate between the two SCD subgroups (\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Baseline plasma A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      may help identify people with SCD and predict SCD progression. The role of plasma A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      levels as well as their upward trends from baseline in cases of SCD that progress to mild cognitive impairment and Alzheimer\u2019s disease require further investigation.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnagi.2024.1389595","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:23:30Z","timestamp":1715905410000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Longitudinal assessment of plasma biomarkers for early detection of cognitive changes in subjective cognitive decline"],"prefix":"10.3389","volume":"16","author":[{"given":"Cheng-Hao","family":"Hsieh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-An","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Sung","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Kuan","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Kuang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Lin","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guan-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Kai","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chen","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Chi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,17]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1002\/ALZ.12324","article-title":"Elevated plasma neurofilament light predicts a faster rate of cognitive decline over 5 years in participants with objectively-defined subtle cognitive decline and MCI","volume":"17","author":"Bangen","year":"2021","journal-title":"Alzheimers Dement."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/ARCHPSYC.1961.01710120031004","article-title":"An inventory for measuring depression","volume":"4","author":"Beck","year":"1961","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1080\/00221309.1985.9711004","article-title":"Learning and retrieval rate of words presented auditorily and visually","volume":"112","author":"Brand","year":"1985","journal-title":"J. Gen. Psychol."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"338ra66","DOI":"10.1126\/scitranslmed.aaf2362","article-title":"Tau and ab imaging, CSF measures, and cognition in Alzheimer\u2019s disease","volume":"8","author":"Brier","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0010-9452(96)80049-9","article-title":"Bizarre responses, rule detection and frontal lobe lesions","volume":"32","author":"Burgess","year":"1996","journal-title":"Cortex"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","article-title":"The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research","volume":"28","author":"Buysse","year":"1989","journal-title":"Psychiatry Res."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"13984","DOI":"10.1038\/S41598-019-50315-9","article-title":"Plasma A\u03b242 and Total tau predict cognitive decline in amnestic mild cognitive impairment","volume":"9","author":"Chen","year":"2019","journal-title":"Sci. Rep."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2147\/NDT.S123428","article-title":"From mild cognitive impairment to subjective cognitive decline: conceptual and methodological evolution","volume":"13","author":"Cheng","year":"2017","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3389\/FNEUR.2019.00715","article-title":"Plasma amyloid Beta and tau levels are predictors of post-stroke cognitive impairment: a longitudinal study","volume":"10","author":"Chi","year":"2019","journal-title":"Front. Neurol."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"102182","DOI":"10.1016\/J.NANO.2020.102182","article-title":"Nanoparticle-based immunomagnetic assay of plasma biomarkers for differentiating dementia and prodromal states of Alzheimer\u2019s disease - a cross-validation study","volume":"28","author":"Chiu","year":"2020","journal-title":"Nanomedicine"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.2174\/156720512804142967","article-title":"New assay for old markers-plasma Beta amyloid of mild cognitive impairment and Alzheimer\u2019s disease","volume":"9","author":"Chiu","year":"2012","journal-title":"Curr. Alzheimer Res."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1021\/CN400129P","article-title":"Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer\u2019s disease","volume":"4","author":"Chiu","year":"2013","journal-title":"ACS Chem. Neurosci."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-23746-0","article-title":"Plasma biomarkers of Alzheimer\u2019s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations","volume":"12","author":"Cullen","year":"2021","journal-title":"Nat. Commun."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/S13195-018-0444-1","article-title":"Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundaci\u00f3 ACE healthy brain initiative (FACEHBI)","volume":"10","author":"De Rojas","year":"2018","journal-title":"Alzheimers Res. Ther."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/JCP.20602","article-title":"Cerebrospinal fluid tau, A\u00df, and phosphorylated tau protein for the diagnosis of Alzheimer\u2019s disease","volume":"208","author":"Formichi","year":"2006","journal-title":"J. Cell. Physiol."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"100063","DOI":"10.1016\/J.BIONPS.2023.100063","article-title":"Biomarkers of Alzheimer\u2019s disease: past, present and future clinical use","volume":"8","author":"Georgakas","year":"2023","journal-title":"Biomark Neuropsychiatry"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1159\/000524390","article-title":"Alzheimer\u2019s disease plasma biomarkers distinguish clinical diagnostic groups in memory clinic patients","volume":"51","author":"Gerards","year":"2022","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1007\/s00415-022-11055-5","article-title":"Plasma neurofilament light chain as a biomarker of Alzheimer\u2019s disease in subjective cognitive decline and mild cognitive impairment","volume":"269","author":"Giacomucci","year":"2022","journal-title":"J. Neurol."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1212\/WNL.0000000000203114","article-title":"Plasma p-tau181 as a promising non-invasive biomarker of Alzheimer\u2019s disease pathology in subjective cognitive decline","volume":"100","author":"Giacomucci","year":"2023","journal-title":"Neurology"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"15317","DOI":"10.1074\/JBC.M110.209296","article-title":"Seeding of normal tau by pathological tau conformers drives pathogenesis of Alzheimer-like tangles","volume":"286","author":"Guo","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"683689","DOI":"10.3389\/fnagi.2022.683689","article-title":"Diagnostic accuracy of blood-based biomarker panels: a systematic review","volume":"14","author":"Hardy-Sosa","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"7307","DOI":"10.3390\/IJMS23137307","article-title":"Tau as a biomarker of neurodegeneration","volume":"23","author":"Holper","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13195-023-01273-Y\/FIGURES\/3","article-title":"Impacts of baseline biomarkers on cognitive trajectories in subjective cognitive decline: the CoSCo prospective cohort study","volume":"15","author":"Hong","year":"2023","journal-title":"Alzheimers Res. Ther."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3233\/ADR-210310","article-title":"Assessment of high risk for Alzheimer\u2019s disease using plasma biomarkers in subjects with Normal cognition in Taiwan: a preliminary study","volume":"5","author":"Hu","year":"2021","journal-title":"J. Alzheimers Dis. Rep."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"889101","DOI":"10.3389\/FNAGI.2022.889101","article-title":"Plasma phosphorylated-tau181 is a predictor of post-stroke cognitive impairment: a longitudinal study","volume":"14","author":"Huang","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/J.JALZ.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"key":"ref001","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/JCP.0000000000000941","article-title":"Digit symbol substitution test: the case for sensitivity over specificity in neuropsychological testing","volume":"38","author":"Jaeger","year":"2018","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/JAMANEUROL.2020.4201","article-title":"Associations of plasma Phospho-Tau217 levels with tau positron emission tomography in early Alzheimer disease","volume":"78","author":"Janelidze","year":"2021","journal-title":"JAMA Neurol."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1474-4422(19)30368-0","article-title":"The characterisation of subjective cognitive decline","volume":"19","author":"Jessen","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/J.JALZ.2014.01.001","article-title":"A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer\u2019s disease","volume":"10","author":"Jessen","year":"2014","journal-title":"Alzheimers Dement."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3389\/FNAGI.2020.00212","article-title":"The validation of multifactor model of plasma A\u03b2 42 and Total-tau in combination with MoCA for diagnosing probable Alzheimer disease","volume":"12","author":"Jiao","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts","volume":"19","author":"Karikari","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/BRAIN\/AWAA403","article-title":"Population-based blood screening for preclinical Alzheimer\u2019s disease in a British birth cohort at age 70","volume":"144","author":"Keshavan","year":"2021","journal-title":"Brain"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"178","DOI":"10.14283\/JPAD.2023.15","article-title":"Predictive utility of plasma amyloid and tau for cognitive decline in cognitively normal adults","volume":"10","author":"Lee","year":"2023","journal-title":"J. Prev Alzheimers Dis."},{"key":"ref36","first-page":"53","article-title":"Biomarkers with plasma amyloid \u03b2 and tau protein assayed by Immunomagnetic reduction in patients with amnestic mild cognitive impairment and Alzheimer\u2019s disease","volume":"31","author":"Lee","year":"2022","journal-title":"Acta Neurol. Taiwanica"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1007\/S43440-020-00107-0","article-title":"Clinical significance of fluid biomarkers in Alzheimer\u2019s disease","volume":"72","author":"Lewczuk","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13195-020-00652-z","article-title":"The role of interleukin-33 in patients with mild cognitive impairment and Alzheimer\u2019s disease","volume":"12","author":"Liang","year":"2020","journal-title":"Alzheimers Res. Ther."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"670115","DOI":"10.3389\/fnagi.2021.670115","article-title":"Better identification of cognitive decline with Interleukin-2 than with amyloid and tau protein biomarkers in amnestic mild cognitive impairment","volume":"13","author":"Liang","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1003325","DOI":"10.3389\/FPSYG.2022.1003325","article-title":"Comparing the effects of olfactory-based sensory stimulation and board game training on cognition, emotion, and blood biomarkers among individuals with dementia: a pilot randomized controlled trial","volume":"13","author":"Lin","year":"2022","journal-title":"Front. Psychol."},{"key":"ref58","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3390\/LIFE13030613","article-title":"Continuous positive airway pressure reduces plasma neurochemical levels in patients with OSA: a pilot study","volume":"13","author":"Liu","year":"2023","journal-title":"Life"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1177\/1073191115602552","article-title":"The trail making test: association with other neuropsychological measures and normative values for adults aged 55 years and older from a Spanish-speaking population-based sample","volume":"24","author":"Llin\u00e0s-Regl\u00e0","year":"2017","journal-title":"Assessment"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/S40120-019-00167-2","article-title":"Advance in plasma AD Core biomarker development: current findings from immunomagnetic reduction-based SQUID technology","volume":"8","author":"Lue","year":"2019","journal-title":"Neurol. Ther."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3389\/FNAGI.2017.00226","article-title":"Plasma levels of A\u03b242 and tau identified probable Alzheimer\u2019s dementia: findings in two cohorts","volume":"9","author":"Lue","year":"2017","journal-title":"Front. Aging Neurosci."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3389\/FNCEL.2014.00113","article-title":"The role of extracellular tau in the spreading of neurofibrillary pathology","volume":"8","author":"Medina","year":"2014","journal-title":"Front. Cell. Neurosci."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/ACPS.12336","article-title":"Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: meta-analysis","volume":"130","author":"Mitchell","year":"2014","journal-title":"Acta Psychiatr. Scand."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/JAMA.2020.12134","article-title":"Discriminative accuracy of plasma Phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"key":"ref47","first-page":"1060","volume-title":"JAMA Neurol.","author":"Palmqvist","year":"2019"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","article-title":"Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures","volume":"27","author":"Palmqvist","year":"2021","journal-title":"Nat. Med."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"832700","DOI":"10.3389\/FNAGI.2022.832700","article-title":"Non-linear character of plasma amyloid beta over the course of cognitive decline in Alzheimer\u2019s continuum","volume":"14","author":"Pan","year":"2022","journal-title":"Front. Aging Neurosci."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13195-023-01341-3\/TABLES\/4","article-title":"Subjective cognitive complaints and blood biomarkers of neurodegenerative diseases: a longitudinal cohort study","volume":"15","author":"Perna","year":"2023","journal-title":"Alzheimers Res. Ther."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"189ra77","DOI":"10.1126\/scitranslmed.3005615","article-title":"Increased in vivo amyloid-b42 production, exchange, and loss in presenilin mutation carriers","volume":"5","author":"Potter","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref52","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1017\/S1355617700001697","article-title":"The structure of normal human attention: the test of everyday attention","volume":"2","author":"Robertson","year":"1996","journal-title":"J. Int. Neuropsychol. Soc."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/nprot.2006.115","article-title":"Clinical and empirical applications of the Rey\u2013Osterrieth complex Figure test","volume":"1","author":"Shin","year":"2006","journal-title":"Nat. Protoc."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/J.JALZ.2018.10.003","article-title":"Subjective cognitive decline and rates of incident Alzheimer\u2019s disease and non-Alzheimer\u2019s disease dementia","volume":"15","author":"Slot","year":"2019","journal-title":"Alzheimers Dement."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3390\/BIOS12100883","article-title":"Applications of Immunomagnetic reduction technology as a biosensor in therapeutic evaluation of Chinese herbal medicine in Tauopathy alleviation of an AD Drosophila model","volume":"12","author":"Su","year":"2022","journal-title":"Biosensors"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/NRNEUROL.2015.119","article-title":"Clearance systems in the brain-implications for Alzheimer disease","volume":"11","author":"Tarasoff-Conway","year":"2015","journal-title":"Nat. Rev. Neurol."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"753","DOI":"10.15585\/MMWR.MM6727A1","article-title":"Subjective cognitive decline among adults aged \u226545 years \u2014 United States, 2015\u20132016","volume":"67","author":"Taylor","year":"2022","journal-title":"MMWR Morb. Mortal Wkly. Rep."},{"key":"ref59","doi-asserted-by":"publisher","first-page":"e12238","DOI":"10.1002\/DAD2.12238","article-title":"Objective subtle cognitive decline and plasma phosphorylated tau181: early markers of Alzheimer\u2019s disease-related declines","volume":"13","author":"Thomas","year":"2021","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.3390\/JCM8111893","article-title":"Associations between plasma biomarkers and cognition in patients with Alzheimer\u2019s disease and amnestic mild cognitive impairment: a cross-sectional and longitudinal study","volume":"8","author":"Tsai","year":"2019","journal-title":"J. Clin. Med."},{"key":"ref61","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jpsychires.2020.06.006","article-title":"Indicators of rapid cognitive decline in amnestic mild cognitive impairment: the role of plasma biomarkers using magnetically labeled immunoassays","volume":"129","author":"Tsai","year":"2020","journal-title":"J. Psychiatr. Res."},{"key":"ref62","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1021\/CN500101J","article-title":"Plasma A\u03b2 but not tau is related to brain PiB retention in early Alzheimer\u2019s disease","volume":"5","author":"Tzen","year":"2014","journal-title":"ACS Chem. Neurosci."},{"key":"ref63","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/J.JALZ.2012.08.004","article-title":"Cerebrospinal fluid A\u03b242 is the best predictor of clinical progression in patients with subjective complaints","volume":"9","author":"van Harten","year":"2013","journal-title":"Alzheimers Dement."},{"key":"ref64","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1002\/ANA.25334","article-title":"Plasma amyloid as Prescreener for the earliest Alzheimer pathological changes","volume":"84","author":"Verberk","year":"2018","journal-title":"Ann. Neurol."},{"key":"ref65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13195-020-00682-7\/FIGURES\/5","article-title":"Combination of plasma amyloid beta(1-42\/1-40)and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology","volume":"12","author":"Verberk","year":"2020","journal-title":"Alzheimers Res. Ther."},{"key":"ref002","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1007\/978-0-387-79948-3_1288","article-title":"Digit Span","author":"Wambach","year":"2011","journal-title":"Encycl. Clin. Neuropsychol."},{"key":"ref66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm9113452","article-title":"Diagnostic utility of selected serum dementia biomarkers: amyloid \u03b2-40, amyloid \u03b2 \u221242, tau protein, and YKL-40: a review","volume":"9","author":"Wilczy\u0144ska","year":"2020","journal-title":"J. Clin. Med."},{"key":"ref67","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/0028-3932(87)90024-8","article-title":"Frontal lesions and sustained attention","volume":"25","author":"Wilkins","year":"1987","journal-title":"Neuropsychologia"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1016\/J.JMMM.2008.05.048","article-title":"Dual immobilization and magnetic manipulation of magnetic nanoparticles","volume":"320","author":"Yang","year":"2008","journal-title":"J. Magn. Magn. Mater."},{"key":"ref69","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/S40120-020-00215-2","article-title":"Immunomagnetic reduction detects plasma A\u03b21-42 levels as a potential dominant Indicator predicting cognitive decline","volume":"9","author":"Yang","year":"2020","journal-title":"Neurol. Ther."},{"key":"ref70","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/CM9.0000000000002566","article-title":"Progress in blood biomarkers of subjective cognitive decline in preclinical Alzheimer\u2019s disease","volume":"136","author":"Yu","year":"2023","journal-title":"Chin. Med. J."},{"key":"ref71","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1097\/CM9.0000000000002851","article-title":"Subjective cognitive decline domain improves accuracy of plasma A\u03b242\/A\u03b240 for preclinical Alzheimer\u2019s disease diagnosis: the SILCODE study","volume":"137","author":"Zhang","year":"2024","journal-title":"Chin. Med. J."},{"key":"ref72","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/J.1600-0447.1983.TB09716.X","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr. Scand."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2024.1389595\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:23:36Z","timestamp":1715905416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2024.1389595\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,17]]},"references-count":72,"alternative-id":["10.3389\/fnagi.2024.1389595"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2024.1389595","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,17]]},"article-number":"1389595"}}